,

RxPONDER Study Results demonstrate that the Oncotype DX test can now spare chemotherapy use in the majority of women with node-positive early-stage breast cancer


The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test

RxPONDER Clinical Trial Key Findings

  • The majority of HR+, HER2-, N1 patients can be spared chemotherapy when decisions are guided with the Oncotype DX test
  • Postmenopausal women with 1-3 positive nodes and Recurrence Score result 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1- 3 positive nodes and Recurrence Score result 0-25 significantly benefit from chemotherapy
  • RxPONDER study results are expected to be practice-changing for N1 HR+, HER2-, early breast cancer patients


RxPONDER Clinical Trial Design


RxPONDER graphic
  • RxPONDER, independently led by the SWOG Cancer Research Network, is one of the largest clinical trials for patients with HR+, HER2- early breast cancer and N1 disease
  • The trial was designed to determine the effect of chemotherapy, if any, in patients who had a Recurrence Score result 0-25


VIEW VIDEO:
Kevin Kalinsky, MD Presents Early RxPONDER data at SABCS 2020

 

Enhancing the Utility of the Oncotype DX Breast Recurrence Score Test

Speaker Dr. Christy Russell, Senior Director of Medical Affairs at Exact Sciences, reviews data that were presented at SABCS 2020: RxPONDER, ADAPT and RSClin Education Tool


Making cancer care smarter.™